» Articles » PMID: 4044831

Hepatic and Renal Metabolism Before and After Portasystemic Shunts in Patients with Cirrhosis

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1985 Sep 1
PMID 4044831
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatic cirrhosis with portal hypertension and gastroesophageal hemorrhage is a disease complex that continues to be treated by surgical portasystemic shunts. Whether or not a reduction or diversion of portal blood flow to the liver adversely affects the ability of the liver to maintain fuel homeostasis via gluconeogenesis, glycogenolysis, and ketogenesis is unknown. 11 patients with biopsy-proven severe hepatic cirrhosis were studied before and after distal splenorenal or mesocaval shunts. Hepatic, portal, and renal blood flow rates and glucose, lactate, pyruvate, glycerol, amino acids, ketone bodies, free fatty acids, and triglyceride arteriovenous concentration differences were determined to calculate net precursor-product exchange rates across the liver, gut, and kidney. The study showed that hepatic contribution of glucose and ketone bodies and the caloric equivalents of these fuels delivered to the blood was not adversely affected by either a distal splenorenal or mesocaval shunt. In addition to these general observations, isolated findings emerged. Mesocaval shunts reversed portal venous blood and functionally converted this venous avenue into hepatic venous blood. The ability of the kidney to make a substantial net contribution of ketone bodies to the blood was also observed.

Citing Articles

Sarcopenia and a physiologically low respiratory quotient in patients with cirrhosis: a prospective controlled study.

Glass C, Hipskind P, Tsien C, Malin S, Kasumov T, Shah S J Appl Physiol (1985). 2013; 114(5):559-65.

PMID: 23288550 PMC: 3615594. DOI: 10.1152/japplphysiol.01042.2012.


Interorgan ammonia trafficking in liver disease.

Olde Damink S, Jalan R, Dejong C Metab Brain Dis. 2008; 24(1):169-81.

PMID: 19067143 DOI: 10.1007/s11011-008-9122-5.


Ammonia and hepatic encephalopathy: the more things change, the more they remain the same.

Shawcross D, Olde Damink S, Butterworth R, Jalan R Metab Brain Dis. 2005; 20(3):169-79.

PMID: 16167195 DOI: 10.1007/s11011-005-7205-0.


Metabolism of energy-yielding substrates in patients with liver cirrhosis.

Muller M, Boker K, Selberg O Clin Investig. 1994; 72(8):568-79.

PMID: 7819712 DOI: 10.1007/BF00227447.

References
1.
BRANNON E, MERRILL A, WARREN J, Stead E . THE CARDIAC OUTPUT IN PATIENTS WITH CHRONIC ANEMIA AS MEASURED BY THE TECHNIQUE OF RIGHT ATRIAL CATHETERIZATION. J Clin Invest. 1945; 24(3):332-6. PMC: 435462. DOI: 10.1172/JCI101610. View

2.
Garber A, MENZEL P, Boden G, Owen O . Hepatic ketogenesis and gluconeogenesis in humans. J Clin Invest. 1974; 54(4):981-9. PMC: 301639. DOI: 10.1172/JCI107839. View

3.
MacDougall B, Westaby D, Theodossi A, Dawson J, Williams R . Increased long-term survival in variceal haemorrhage using injection sclerotherapy. Results of a controlled trial. Lancet. 1982; 1(8264):124-7. DOI: 10.1016/s0140-6736(82)90378-6. View

4.
Owen O, REICHLE F, Mozzoli M, KREULEN T, Patel M, Elfenbein I . Hepatic, gut, and renal substrate flux rates in patients with hepatic cirrhosis. J Clin Invest. 1981; 68(1):240-52. PMC: 370791. DOI: 10.1172/jci110240. View

5.
Burroughs A, Jenkins W, Sherlock S, Dunk A, Walt R, Osuafor T . Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med. 1983; 309(25):1539-42. DOI: 10.1056/NEJM198312223092502. View